Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 48 articles: HTML format Text format

Single Articles

February 2019
1. KAWATA T, Higashimori M, Itoh Y, Tomkinson H, et al
   Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2019 Feb 14. pii: 10.1007/s00280-019-03788.
   PubMed     Text format     Abstract available
   
   
   
2. YAMAGUCHI O, Kaira K, Mouri A, Shiono A, et al
   Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
   Cancer Chemother Pharmacol. 2019 Feb 13. pii: 10.1007/s00280-019-03790.
   PubMed     Text format     Abstract available
   
   
   December 2018
3. GUSELLA M, Pasini F, Caruso D, Barile C, et al
   Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
   Cancer Chemother Pharmacol. 2018 Dec 12. pii: 10.1007/s00280-018-3751.
   PubMed     Text format     Abstract available
   
   
   
4. QUAN YH, Lim JY, Choi BH, Choi Y, et al
   Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
   Cancer Chemother Pharmacol. 2018 Dec 4. pii: 10.1007/s00280-018-3737.
   PubMed     Text format     Abstract available
   
   
   October 2018
5. HE Y, Xie H, Yu P, Jiang S, et al
   FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
   Cancer Chemother Pharmacol. 2018 Oct 9. pii: 10.1007/s00280-018-3697.
   PubMed     Text format     Abstract available
   
   
   
6. ODA N, Hotta K, Ninomiya K, Minami D, et al
   A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
   Cancer Chemother Pharmacol. 2018 Oct 1. pii: 10.1007/s00280-018-3694.
   PubMed     Text format     Abstract available
   
   
   June 2018
7. HUANG C, Liu S, Tong X, Fan H, et al
   Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.
   Cancer Chemother Pharmacol. 2018 Jun 8. pii: 10.1007/s00280-018-3586.
   PubMed     Text format     Abstract available
   
   
   May 2018
8. MORCOS PN, Nueesch E, Jaminion F, Guerini E, et al
   Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2018 May 10. pii: 10.1007/s00280-018-3597.
   PubMed     Text format     Abstract available
   
   
   
9. IMAI H, Minemura H, Sugiyama T, Yamada Y, et al
   Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
   Cancer Chemother Pharmacol. 2018 May 8. pii: 10.1007/s00280-018-3596.
   PubMed     Text format     Abstract available
   
   
   
10. KOBA T, Minami S, Nishijima-Futami Y, Masuhiro K, et al
    Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3598.
    PubMed     Text format     Abstract available
    
    
    
11. SMIT EF, Garon EB, Reck M, Cappuzzo F, et al
    Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 2. pii: 10.1007/s00280-018-3560.
    PubMed     Text format     Abstract available
    
    
    April 2018
12. FUJITA K, Uchida N, Kanai O, Okamura M, et al
    Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Cancer Chemother Pharmacol. 2018 Apr 19. pii: 10.1007/s00280-018-3585.
    PubMed     Text format     Abstract available
    
    
    
13. NIHEI S, Sato J, Harada T, Kuyama S, et al
    Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
    Cancer Chemother Pharmacol. 2018 Apr 12. pii: 10.1007/s00280-018-3580.
    PubMed     Text format     Abstract available
    
    
    
14. FUKUSHIMA T, Wakatsuki Y, Kobayashi T, Sonehara K, et al
    Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Apr 11. pii: 10.1007/s00280-018-3573.
    PubMed     Text format     Abstract available
    
    
    February 2018
15. CUI J, Wang MC, Zhang YM, Ren MZ, et al
    Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 26. pii: 10.1007/s00280-018-3539.
    PubMed     Text format     Abstract available
    
    
    
16. SIENA L, Cipollina C, Di Vincenzo S, Ferraro M, et al
    Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Cancer Chemother Pharmacol. 2018 Feb 12. pii: 10.1007/s00280-018-3538.
    PubMed     Text format     Abstract available
    
    
    January 2018
17. TAIRA T, Yoh K, Nagase S, Kubota K, et al
    Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Jan 31. pii: 10.1007/s00280-018-3530.
    PubMed     Text format     Abstract available
    
    
    
18. WANG S, Gao A, Liu J, Sun Y, et al
    First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Cancer Chemother Pharmacol. 2018 Jan 11. pii: 10.1007/s00280-017-3516.
    PubMed     Text format     Abstract available
    
    
    December 2017
19. FEDORCHUK O, Susak Y, Rudyk M, Senchylo N, et al
    Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.
    Cancer Chemother Pharmacol. 2017 Dec 30. pii: 10.1007/s00280-017-3503.
    PubMed     Text format     Abstract available
    
    
    
20. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
    Cancer Chemother Pharmacol. 2017 Dec 11. pii: 10.1007/s00280-017-3498.
    PubMed     Text format     Abstract available
    
    
    November 2017
21. MASUDA T, Hirano C, Horimasu Y, Nakashima T, et al
    The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 15. doi: 10.1007/s00280-017-3476.
    PubMed     Text format     Abstract available
    
    
    
22. SAKURAI R, Tomizawa Y, Yoshii A, Miura Y, et al
    A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 9. doi: 10.1007/s00280-017-3439.
    PubMed     Text format     Abstract available
    
    
    
23. SCHMID U, Liesenfeld KH, Fleury A, Dallinger C, et al
    Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Cancer Chemother Pharmacol. 2017 Nov 8. doi: 10.1007/s00280-017-3452.
    PubMed     Text format     Abstract available
    
    
    
24. MURAKAMI S, Saito H, Kondo T, Ito H, et al
    Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 7. doi: 10.1007/s00280-017-3460.
    PubMed     Text format     Abstract available
    
    
    October 2017
25. CHEN K, Yu X, Wang H, Huang Z, et al
    Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2017 Oct 24. doi: 10.1007/s00280-017-3464.
    PubMed     Text format     Abstract available
    
    
    
26. SRINIVASAN G, Sidhu GS, Williamson EA, Jaiswal AS, et al
    Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Cancer Chemother Pharmacol. 2017;80:861-867.
    PubMed     Text format     Abstract available
    
    
    September 2017
27. ZHANG H, Hu B, Wang Z, Zhang F, et al
    miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Cancer Chemother Pharmacol. 2017 Sep 27. doi: 10.1007/s00280-017-3435.
    PubMed     Text format     Abstract available
    
    
    
28. IKEZAWA Y, Asahina H, Oizumi S, Watanabe M, et al
    A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
    Cancer Chemother Pharmacol. 2017 Sep 13. doi: 10.1007/s00280-017-3432.
    PubMed     Text format     Abstract available
    
    
    
29. SATO J, Morikawa N, Chiba R, Nihei S, et al
    Case series on the association between blood levels and side effects of afatinib maleate.
    Cancer Chemother Pharmacol. 2017;80:545-553.
    PubMed     Text format     Abstract available
    
    
    August 2017
30. REN K, Xu R, Huang J, Zhao J, et al
    Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2017;80:243-250.
    PubMed     Text format     Abstract available
    
    
    July 2017
31. IMAI H, Sugiyama T, Tamura T, Minemura H, et al
    A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3403.
    PubMed     Text format     Abstract available
    
    
    
32. KENMOTSU H, Ohde Y, Wakuda K, Nakashima K, et al
    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3400.
    PubMed     Text format     Abstract available
    
    
    
33. ZHAO XM, Zhao J, Wu XH, Luo ZG, et al
    Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Cancer Chemother Pharmacol. 2017 Jul 28. doi: 10.1007/s00280-017-3399.
    PubMed     Text format     Abstract available
    
    
    
34. KIM HK, Heo MH, Lee HS, Sun JM, et al
    Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Cancer Chemother Pharmacol. 2017 Jul 21. doi: 10.1007/s00280-017-3396.
    PubMed     Text format     Abstract available
    
    
    
35. SHIROYAMA T, Tamiya M, Minami S, Takata S, et al
    Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
    Cancer Chemother Pharmacol. 2017 Jul 7. doi: 10.1007/s00280-017-3385.
    PubMed     Text format     Abstract available
    
    
    June 2017
36. XU L, Fu Y, Li Y, Han X, et al
    Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3355.
    PubMed     Text format     Abstract available
    
    
    
37. PARK S, Kang BW, Lee SJ, Yoon S, et al
    Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3348.
    PubMed     Text format     Abstract available
    
    
    
38. ASPESLAGH S, Shailubhai K, Bahleda R, Gazzah A, et al
    Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
    Cancer Chemother Pharmacol. 2017;79:1257-1265.
    PubMed     Text format     Abstract available
    
    
    May 2017
39. MILAKI G, Messaritakis I, Koinis F, Kotsakis A, et al
    Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 May 18. doi: 10.1007/s00280-017-3339.
    PubMed     Text format     Abstract available
    
    
    
40. CHEN X, Liu L, Guo Z, Liang W, et al
    UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 May 13. doi: 10.1007/s00280-017-3306.
    PubMed     Text format     Abstract available
    
    
    
41. OKUDA Y, Sato K, Sudo K, Hasegawa Y, et al
    Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Cancer Chemother Pharmacol. 2017;79:1013-1020.
    PubMed     Text format     Abstract available
    
    
    April 2017
42. FUJIWARA T, Kenmotsu H, Naito T, Kawamura T, et al
    The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3324.
    PubMed     Text format     Abstract available
    
    
    
43. NISHIJIMA-FUTAMI Y, Minami S, Futami S, Koba T, et al
    Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3321.
    PubMed     Text format     Abstract available
    
    
    
44. LAU YY, Gu W, Lin T, Viraswami-Appanna K, et al
    Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 19. doi: 10.1007/s00280-017-3308.
    PubMed     Text format     Abstract available
    
    
    
45. XIANG T, Kang X, Gong Z, Bai W, et al
    XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Cancer Chemother Pharmacol. 2017;79:791-800.
    PubMed     Text format     Abstract available
    
    
    March 2017
46. WAKELEE HA, Gettinger S, Engelman J, Janne PA, et al
    A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 28. doi: 10.1007/s00280-017-3283.
    PubMed     Text format     Abstract available
    
    
    
47. JANG J, Kim HK, Cho BC, Lee KH, et al
    Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3289.
    PubMed     Text format     Abstract available
    
    
    
48. MORCOS PN, Bogman K, Hubeaux S, Sturm-Pellanda C, et al
    Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
    Cancer Chemother Pharmacol. 2017;79:559-568.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: